Equillium, Inc.

NASDAQ:EQ

Biotechnology

Healthcare
$1.10 +1.51%

+$0.05 today

Market cap
$90.56M
Beta
1.76
P/E (TTM)
-15.3
EPS (TTM)
-$0.20
52W Low $0.27High $3.45

Volume 0.89M

Average 0.60M

EQ Income Before Tax

Profit after all operating and non-operating items but before income tax.

Equillium, Inc.NASDAQ: EQ

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$5.31M, compared with -$8.65M a year earlier. Trailing-twelve-month income before tax was -$19.06M.

Context

  • Income before tax grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -$5.31M or moves back toward the trailing-twelve-month quarterly average of -$4.76M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$5.31M-40.7% QoQ
Last fiscal yearDec 2025
-$22.4M-190.7% YoY
LTMMar 2026
-$19.06M-39.8% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+38.6%——
1 year-190.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(22.4M) USD
Year-over-year change
-190.7%

Income Before Tax vs competitors

How EQ compares with its peers on the latest reported figures

  • EQ's LTM Mar 2026 income before tax of -$19.06M is the 5th highest of the 10 companies compared; the peer median is -$24.54M.
  • Its year-over-year change of -39.8% is the 7th highest of 10, against a peer median of -1.8%.
EQ Competitors Peer median
Income Before Tax for EQ and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FBIOFortress Biotech, Inc.LTM Mar 2026$133.28M +225.6%—201.4%
TELOTelomir Pharmaceuticals, Inc. Common StockLTM Mar 2026-$9.22M +26.3%——
COEPCoeptis Therapeutics, Inc.LTM Mar 2026-$12.88M -14.0%—910.7%
CUECue Biopharma, Inc.LTM Mar 2026-$19.02M +53.1%—58.1%
EQEquillium, Inc.LTM Mar 2026-$19.06M -39.8%——
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026-$24.54M -1.8%—1070.3%
OSTXOS Therapies IncorporatedLTM Mar 2026-$35.27M -212.1%——
SPRBSpruce Biosciences, Inc.LTM Mar 2026-$37.19M +32.9%——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$62.51M -395.9%—18764.2%
IPSCCentury Therapeutics, Inc.LTM Mar 2026-$107.85M -435.1%——
Peer median (excluding EQ) -$24.54M-1.8%—910.7%

Competitors are the stored peer set for EQ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue015.76M36.08M41.1M0
Cost of Revenue0000116K
Gross Profit015.76M36.08M41.1M(116K)
Gross Margin—100.0%100.0%100.0%—
Research & Development26.38M37.55M37.04M37.43M12.84M
Selling, General & Admin11.41M17.24M13.57M11.94M10.79M
Operating Expenses37.79M77.84M50.61M49.36M23.63M
Depreciation & Amortization72K118K126K137K116K
EBITDA(37.91M)(61.26M)(12.14M)(7.57M)(22.28M)
EBITDA Margin—-388.7%-33.6%-18.4%—
Operating Income(37.79M)(62.08M)(14.52M)(8.27M)(23.63M)
Operating Margin—-393.9%-40.2%-20.1%—
Interest Income57K420K2.33M1.38M833K
Interest Expense1.07M1.05M491K00
Other Income / Expenses(1.27M)(352K)1.77M563K1.24M
Income Before Tax(39.05M)(62.43M)(12.76M)(7.71M)(22.4M)
Pre-Tax Margin—-396.1%-35.3%-18.8%—
Income Tax Expense00580K361K0
Net Income(38.98M)(62.43M)(13.34M)(8.07M)(22.4M)
Net Margin—-396.1%-37.0%-19.6%—
EPS (Basic)(1.35)(3.19)(0.38)(0.23)(0.39)
EPS (Diluted)(1.35)(3.19)(0.38)(0.23)(0.39)
Weighted Avg Shares28.81M33.73M34.73M35.36M91.88M
Weighted Avg Shares (Diluted)28.81M33.73M34.73M35.36M91.88M

Equillium, Inc.

NASDAQ:EQ

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.